Breast Cancer News and Research

Latest Breast Cancer News and Research

Klerokinesis may prevent some cancers from developing

Researchers at the University of Wisconsin Carbone Cancer Center have discovered a new form of cell division in human cells.

18 Dec 2012

PRSS3 enzyme linked to aggressive prostate cancer

Researchers at Mayo Clinic's campus in Florida have identified an enzyme specifically linked to aggressive prostate cancer, and have also developed a compound that inhibits the ability of this molecule to promote the metastatic spread of the cancer.

18 Dec 2012

New MIT technology may help make cancer biomarker detection much easier

Finding ways to diagnose cancer earlier could greatly improve the chances of survival for many patients. One way to do this is to look for specific proteins secreted by cancer cells, which circulate in the bloodstream. However, the quantity of these biomarkers is so low that detecting them has proven difficult.

17 Dec 2012

Lapatinib benefits found for HER2-positive early-stage patients

Women with early-stage, HER2-positive breast cancer who are unable to use trastuzumab may benefit from adjuvant lapatinib treatment, suggest phase III trial findings published in Lancet Oncology.

17 Dec 2012

18FDG–PET–CT improves breast cancer staging

A prospective study has shown fluorodeoxyglucose positron emission tomography/computed tomography to be a powerful tool for the detection of nodal and distant metastatic disease in patients with breast cancer.

17 Dec 2012

Study describes new, paradoxical characteristics of HER2-negative breast cancer

A multicenter study led by researchers at UC Davis describes new, paradoxical characteristics of the most common type of breast cancer. The findings shed light on how the disease can evade treatment and could improve diagnosis and treatment of breast cancer.

15 Dec 2012

Researchers identify how RecA protein helps broken DNA find way to bridge the gap

Every time a human or bacterial cell divides it first must copy its DNA. Specialized proteins unzip the intertwined DNA strands while others follow and build new strands, using the originals as templates. Whenever these proteins encounter a break - and there are many - they stop and retreat, allowing a new cast of molecular players to enter the scene.

14 Dec 2012

IOF kicks off 3rd Asia-Pacific Osteoporosis Meeting

Doctors and researchers from across the Asia-Pacific gathered today for the opening of the International Osteoporosis Foundation's (IOF) 3rd Asia-Pacific Osteoporosis Meeting, taking place at the Kuala Lumpur Convention Centre until December 16, 2012.

14 Dec 2012

Pairing statins with cyclin-dependent kinase inhibitors might effectively treat melanomas

A novel approach to identifying potential anticancer drug combinations revealed that pairing cholesterol-reducing drugs called statins with cyclin-dependent kinase inhibitors might provide an effective approach to treating intractable melanomas driven by mutations in the NRAS and KRAS gene.

14 Dec 2012

Breast cancer patients' recurrence fear distorted

The majority of women who undergo contralateral prophylactic mastectomy do so out of fear that their breast cancer will recur, rather than because they have a clinically high risk for recurrence, indicate US study results.

13 Dec 2012

China SFDA approves Veridex’s CellSearch test for women with metastatic breast cancer

Veridex, LLC today announced approval from the China State Food & Drug Administration (SFDA) for the CellSearch circulating tumor cell (CTC) test as an in vitro diagnostic for women with metastatic breast cancer.

13 Dec 2012

TSEC strategy can benefit postmenopausal women

Investigators at Wake Forest Baptist Medical Center have concluded research on a new postmenopausal hormone therapy that shows promise as an effective treatment for menopausal symptoms and the prevention of osteoporosis without increasing the risk for heart disease or breast cancer.

13 Dec 2012

First Warning Systems announces Letter of Intent with UniCorp Biotech

First Warning Systems, Inc. announced a Letter of Intent with Budapest, Hungary, European Union based medical products marketing partner, UniCorp Biotech.

13 Dec 2012

Delayed childbearing may protect against triple-negative breast cancer

Younger women who wait at least 15 years after their first menstrual period to give birth to their first child may reduce their risk of an aggressive form of breast cancer by up to 60 percent, according to a Fred Hutchinson Cancer Research Center study.

12 Dec 2012

U-M devises new system to capture and study circulating tumor cells

A glass plate with a nanoscale roughness could be a simple way for scientists to capture and study the circulating tumor cells that carry cancer around the body through the bloodstream.

12 Dec 2012

Merrimack announces results from MM-302 Phase I trial on advanced HER2 positive breast cancer

Merrimack Pharmaceuticals, Inc. today announced Phase I clinical trial results for MM-302, the company's novel agent for the treatment of advanced HER2 positive (HER2+ or ErbB2+) breast cancer.

11 Dec 2012

Viewpoints: Girding for a 'beloved' Medicare fight; Two views about health law's employer mandate; Doctors fear 'SGR cliff'

It's a shame that Republicans are playing into Mr. Obama's hands, negotiating in public among themselves, ... Tennessee Senator Bob Corker made the case for this strategic retreat on "Fox News Sunday," arguing that if Republicans raise tax rates as Mr. Obama wants, "the focus then shifts to entitlements and maybe it puts us in a place where we actually can do something that really saves the nation."

10 Dec 2012

ATLAS holds up 10-year tamoxifen regime

Results from the ATLAS study indicate that women with estrogen receptor-positive breast cancer should consider taking tamoxifen for up to 10 years after diagnosis.

10 Dec 2012

New assay test shows positive results for patients with recurrent or metastatic breast cancer

When breast cancer advances, the patient doesn't have the luxury of time. Finding the right type of chemotherapy as quickly as possible is a critical factor for the patient's success and, until now, predicting the patient's sensitivity to chemotherapy has often been a shot in the dark.

10 Dec 2012

Results from eribulin and capecitabine phase III comparison trial on metastatic breast cancer

Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, showed that eribulin demonstrated a trend toward improved overall survival.

10 Dec 2012